Medication info

Pioglionmet Tablet 15/850 milligrams

Prescription medicationTabletExpired
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Korea Sintax Pharmaceutical Co., Ltd.
Appearance
White to pale white oval film-coated tablet
Packaging
30 tablets/PTP[(10 tablets/PTPX3)]
Approval status
Expired

MFDS item code 201907469 · Approved 2019.10.28

This product's status changed to Expired on 2024.10.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component, pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their current doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes mellitus may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of this medicine. After administering this medicine to patients or increasing the dose, monitor carefully for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control as measured by FPG does not worsen, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.

Ingredients

Manufacturer
Korea Sintax Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Insulin-independent diabetes
  • abnormal blood sugar control
  • type 2 diabetes
View approved original text

This medication is used to help control blood sugar levels in patients with insulin-independent diabetes, i.e., type 2 diabetes. It is particularly administered as an adjunct therapy when blood sugar control is insufficient with monotherapy using either metformin or pioglitazone. Additionally, it is used when substituting the combination therapy of pioglitazone and metformin. Proper nutritional counseling, weight loss, and exercise should accompany this medication for effective management of type 2 diabetes, which are crucial for enhancing and maintaining the therapeutic effect. This medication complements these treatments and helps improve blood sugar control.

Dosage and Administration

Adult dosage

For treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component, pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine daily and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their current doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes mellitus may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of this medicine. After administering this medicine to patients or increasing the dose, monitor carefully for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control as measured by FPG does not worsen, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.

Precautions

This medication helps in controlling blood sugar levels. However, it should not be administered to patients with impaired renal function or severe heart failure. Moreover, patients with liver dysfunction should also avoid using this medication. It can cause serious side effects such as lactic acidosis; hence, if symptoms such as shortness of breath, muscle pain, fatigue, or abdominal pain occur, immediate consultation with a doctor is necessary. Excessive alcohol consumption increases the risk of side effects, so it is advisable to avoid alcohol during treatment. This medication may exacerbate heart failure symptoms, so careful observation of symptoms like weight gain, edema, and shortness of breath is required. Additionally, patients with a history of bladder cancer should weigh the risks and benefits carefully when using this medication. Pregnant or breastfeeding women should not take this medication, and its safety in pediatric patients has not been established. Regular monitoring of blood sugar, renal function, liver function, and blood tests should be conducted to ensure no abnormalities occur during treatment. When taking this medication with others, it is important to consult a doctor or pharmacist for potential interactions. In the case of overdose, immediate medical attention is necessary. Finally, this medication should be taken regularly alongside meals and exercise, while being cautious of hypoglycemia or other adverse reactions during treatment.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • lethargy
  • myalgia
  • dyspnea
  • asthenia
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 36 more
  • upper respiratory infection
  • diarrhea
  • mixed edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • vision reduction
  • diabetic macular edema
  • liver failure
  • congestive heart failure
  • edema
  • fracture
  • serum transaminase elevation
  • serum creatine phosphokinase elevation
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intraluminal intestinal gas retention
  • elevated serum creatinine
  • increased blood urea
  • macroscopic hematuria
  • urination disorders
  • urgency

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 and 30 degrees Celsius room temperature.

Appearance and packaging

Appearance

White to pale white oval film-coated tablet

Package unit

30 tablets/PTP[(10 tablets/PTPX3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.